Citigroup upgrades LPLA to "Market Outperform" with a stock price of $376.33.Mutual of America Capital Management LLC increases its investment in LPLA by 116.6%, now holding shares valued at approximately $1.85 million.Other institutional investors, including Cullen Frost Bankers Inc. and Camden National Bank, have also raised their stakes in LPL Financial, indicating a positive market outlook.LPL Financial Holdings Inc. (NASDAQ:LPLA) is a prominent player in the financial services sector, providing a platf ...

Group 1 - KPN intends to issue a EUR 500 million Eurobond under its Global Medium Term Note programme to refinance existing debt and for general corporate purposes [1] - KPN is offering to repurchase GBP 400 million of its 5.00% notes due 2026 and up to GBP 300 million of its 5.75% notes due 2029 [2] - The transaction aims to proactively manage KPN's debt structure and reduce near-term refinancing requirements, with specific conditions for the Offers [3] Group 2 - BNP PARIBAS and Citigroup are appointed as Global Co-ordinators for the new bond offering, with several banks acting as Active Bookrunners and Dealer Managers [4] - KPN's announcement includes formal disclosures regarding the Eurobond and Tender Offer [5]

We recently published 10 Big Names Already Crushing This February. Lumentum Holdings Inc. (NASDAQ:LITE) was one of the top performers on Monday. Lumentum Holdings rallied for a second day on Monday, jumping 8.06 percent to close at $423.42 apiece as investors loaded portfolios ahead of its earnings outcome which came out shortly after market close. Earlier, Lumentum Holdings Inc. (NASDAQ:LITE) announced expectations of $630 million to $670 million in net revenues, as well as $1.30 to $1.50 diluted earni ...

Core Viewpoint - Gilead Sciences, Inc. (NASDAQ:GILD) is highlighted as one of the most profitable stocks on NASDAQ, with recent price target increases from Truist Securities and Citigroup indicating strong investor confidence in the company's future performance [1][3]. Group 1: Price Target Adjustments - Truist Securities raised its price target on Gilead Sciences to $145 from $140 while maintaining a Buy rating, citing revisions in estimates for the drug YEZTUGO and updates on upcoming launches [2]. - Citigroup also increased its price target for Gilead Sciences to $156 from $140, maintaining a Buy rating, as part of a broader Q4 preview for biopharmaceutical stocks [3]. Group 2: Company Overview - Gilead Sciences is a biopharmaceutical company focused on developing medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer [4].

Tyler Crowe: It's 2026, and banking is booming. This is Motley Fool Money. Welcome to Motley Fool Money. I'm Tyler Crowe, and today I'm joined by longtime Fool contributors Matt Frankel and Jon Quast. It's that time again, folks, earning season, and we'll discuss earnings today, this proposal from the Trump administration to cap credit card rates because we are talking about banks. Of course, what Thursday show would be complete without talking about stocks on our radar. But first, when I opened up Bloomber ...

Citigroup Inc. (NYSE:C) is preparing for another round of employee layoffs expected in March, following approximately 1,000 job cuts executed earlier this month.The upcoming reductions are expected to primarily affect managing directors and other senior employees across business lines, according to a source cited by Reuters on Thursday, as the bank continues to streamline operations amid a broader restructuring effort.The latest cuts form part of a long-term plan announced two years ago to eliminate 20,000 ...

By Kanishka Ajmera and Rashika Singh Jan 22 (Reuters) - U.S. fintech stocks could gain an edge as Washington leans into a more populist, affordability-driven agenda ahead of ​the November 2026 midterm elections, analysts at Citigroup said in a ‌note. President Donald Trump's latest policy push is prompting investors to reassess parts of the financial ‌sector, with his emphasis on affordability potentially opening the door for fintech challengers instead of traditional lenders, the brokerage said. Compa ...

Group 1 - Moderna, Inc. is a leading biotechnology company known for its mRNA technology, particularly in COVID-19 vaccine development, competing with Pfizer and BioNTech [1] - Citigroup has updated its rating for Moderna to "Neutral," indicating that investors should hold onto the stock, which is currently trading at approximately $41.84 [1][5] - The stock has seen a 6.29% increase, with a daily trading range between $40.55 and $42.30, and a market capitalization of around $16.35 billion [4][5] Group 2 - Investors often focus on stocks that are expected to exceed quarterly earnings estimates, as these can significantly influence stock prices [2] - The Zacks Earnings ESP tool is utilized to identify potential earnings surprises by analyzing recent analyst revisions, which can help investors enhance their returns [3]

The Goldman Sachs Group, Inc. (NYSE:GS) is one of the stocks Jim Cramer put under a microscope. Cramer mentioned the stock during the episode and commented: “The banks rebounded because of beautiful pristine blowouts from BlackRock, from Goldman Sachs, my alma mater, and Morgan Stanley… I told you earlier this week that we needed to see the banks reverse, right, remember, because that’s the best leadership group in the world, and then suddenly, it’s been really bad ever since JPMorgan reported. Well, gues ...

Core Viewpoint - The U.S. stock market experienced a decline primarily due to Nvidia's ban on H200 AI chips in China, which negatively impacted major technology stocks and bank earnings [2][10]. Market Overview - The three major U.S. stock indices fell on January 14, 2026, with Nvidia's decline leading the way, affecting other technology stocks [2]. - Major banks like Citigroup and Wells Fargo reported disappointing fourth-quarter results, contributing to the market's downturn [2]. Investment Strategy - Investors are advised to favor low-leverage stocks over high-growth technology stocks to mitigate risks associated with high-debt companies [3][10]. - Recommended companies include REV Group (REVG), TechnipFMC (FTI), Resmed (RMD), Zurn Elkay Water Solutions (ZWS), and SEI Investments (SEIC), all of which exhibit low leverage and solid growth prospects [3][10]. Significance of Low-Leverage Stocks - Leverage refers to borrowing capital for operations and expansion, typically through debt financing, which can pose risks if not managed properly [5][6]. - Companies with excessive reliance on debt financing may face significant losses during economic downturns, making low-leverage stocks a safer investment choice [6][7]. Debt Analysis - The debt-to-equity ratio is a key metric for assessing a company's financial risk, with lower ratios indicating better solvency [8]. - Investors should focus on stocks with solid earnings growth and low debt-to-equity ratios, especially during earnings seasons [8][10]. Stock Recommendations - **REV Group (REVG)**: Reported a 11.1% year-over-year increase in net sales to $664.4 million and a 62.7% surge in adjusted earnings per share [14][15]. - **TechnipFMC (FTI)**: Awarded a significant contract by BP, with a projected revenue increase of 6.6% for 2026 [16][17]. - **Resmed (RMD)**: Received FDA clearance for an AI-enabled medical device, with an expected 8.4% revenue growth for 2026 [18][19]. - **Zurn Elkay Water Solutions (ZWS)**: Recognized as one of America's Most Responsible Companies, with a projected revenue increase of 5.3% for 2026 [20][21]. - **SEI Investments (SEIC)**: Completed multiple client projects, with a forecasted revenue growth of 9.3% for 2026 [22][23].